These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 24325405)

  • 81. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
    Aoki Y; Sugiyama M; Murata K; Yoshio S; Kurosaki M; Hashimoto S; Yatsuhashi H; Nomura H; Kang JH; Takeda T; Naito S; Kimura T; Yamagiwa Y; Korenaga M; Imamura M; Masaki N; Izumi N; Kage M; Mizokami M; Kanto T
    J Gastroenterol; 2015 Aug; 50(8):894-902. PubMed ID: 25501286
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.
    Lee TH; Tillmann HL; Patel K
    Mol Diagn Ther; 2014 Feb; 18(1):25-38. PubMed ID: 24022240
    [TBL] [Abstract][Full Text] [Related]  

  • 83. IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.
    Ioniţă-Radu F; Raşcanu A; Cheiab B
    Rom J Intern Med; 2011; 49(2):99-104. PubMed ID: 22303600
    [TBL] [Abstract][Full Text] [Related]  

  • 84. IL28B polymorphisms of both recipient and donor cooperate to influence IFN treatment response in HCV recurrence after liver transplantation, but IL28B SNPs of the recipient play a major role in IFN-induced blocking of HCV replication.
    Barbera F; Russelli G; Pipitone L; Pietrosi G; Corsale S; Vizzini G; Gridelli B; Conaldi PG
    New Microbiol; 2015 Apr; 38(2):201-10. PubMed ID: 25938745
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Genetic predictors of the response to the treatment of hepatitis C virus infection.
    Dzekova-Vidimliski P; Nikolov IG; Matevska-Geshkovska N; Boyanova Y; Nikolova N; Romanciuc G; Dumitrascu D; Caloska-Ivanova V; Joksimovic N; Antonov K; Mateva L; Rostaing L; Dimovski A; Sikole A
    Bosn J Basic Med Sci; 2015 Nov; 15(4):55-9. PubMed ID: 26614853
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
    O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
    J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care.
    McHutchison JG
    Liver Int; 2011 Jan; 31 Suppl 1():29-35. PubMed ID: 21205135
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response.
    Resham S; Manzoor S; Imran M; Saalim M; Naseem S; Azam S
    APMIS; 2015 Sep; 123(9):765-71. PubMed ID: 26177560
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?
    Holmes JA; Desmond PV; Thompson AJ
    J Viral Hepat; 2012 Oct; 19(10):677-84. PubMed ID: 22967098
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
    Nordien R; Sonderup MW; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):106-111. PubMed ID: 32657679
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.
    Muir AJ; Gong L; Johnson SG; Lee MT; Williams MS; Klein TE; Caudle KE; Nelson DR;
    Clin Pharmacol Ther; 2014 Feb; 95(2):141-6. PubMed ID: 24096968
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C.
    Zhu DY; Deng XZ; Zhu YM; Li GT; Zhang GQ; Wang LJ; Zhang JH; Xiao W; Zhou ZX; Ding WL
    Arch Virol; 2018 May; 163(5):1253-1262. PubMed ID: 29399747
    [TBL] [Abstract][Full Text] [Related]  

  • 93. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
    Meissner EG; Bon D; Prokunina-Olsson L; Tang W; Masur H; O'Brien TR; Herrmann E; Kottilil S; Osinusi A
    J Infect Dis; 2014 Jun; 209(11):1700-4. PubMed ID: 24367041
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
    Murata K; Sugiyama M; Kimura T; Yoshio S; Kanto T; Kirikae I; Saito H; Aoki Y; Hiramine S; Matsui T; Ito K; Korenaga M; Imamura M; Masaki N; Mizokami M
    J Gastroenterol; 2014 Jan; 49(1):126-37. PubMed ID: 23591768
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B.
    Angelo AL; Cavalcante LN; Abe-Sandes K; Machado TB; Lemaire DC; Malta F; Pinho JR; Lyra LG; Lyra AC
    Clinics (Sao Paulo); 2013 Oct; 68(10):1325-32. PubMed ID: 24212839
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.
    Clark PJ; Thompson AJ; Zhu M; Vock DM; Zhu Q; Ge D; Patel K; Harrison SA; Urban TJ; Naggie S; Fellay J; Tillmann HL; Shianna K; Noviello S; Pedicone LD; Esteban R; Kwo P; Sulkowski MS; Afdhal N; Albrecht JK; Goldstein DB; McHutchison JG; Muir AJ;
    J Viral Hepat; 2012 May; 19(5):332-40. PubMed ID: 22497812
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C.
    Murakawa M; Asahina Y; Nakagawa M; Sakamoto N; Nitta S; Kusano-Kitazume A; Watanabe T; Kawai-Kitahata F; Otani S; Taniguchi M; Goto F; Nishimura-Sakurai Y; Itsui Y; Azuma S; Kakinuma S; Watanabe M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1075-84. PubMed ID: 25611696
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pegylated interferon and ribavirin gone but not forgotten in the era of direct-acting antivirals.
    Pluta M; Pokorska-Śpiewak M; Aniszewska M; Lewandowski Z; Kowalik-Mikołajewska B; Marczyńska M
    Minerva Pediatr (Torino); 2022 Feb; 74(1):23-30. PubMed ID: 33438851
    [TBL] [Abstract][Full Text] [Related]  

  • 99. CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection.
    Suppiah V; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Nattermann J; Mueller T; Riordan S; Stewart GJ; George J; Booth DR; Ahlenstiel G;
    Genes Immun; 2013; 14(5):286-90. PubMed ID: 23594959
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population.
    Zang F; Yue M; Yao Y; Liu M; Fan H; Feng Y; Xia X; Huang P; Yu R
    Epidemiol Infect; 2018 Feb; 146(3):379-385. PubMed ID: 29271328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.